News >

Selinexor Again Shows Promise in Heavily Pretreated Myeloma

Jason M. Broderick @jasoncology
Published: Tuesday, May 01, 2018

blood cells Selinexor induced an overall response rate (ORR) of 25.4% in patients with penta-refractory multiple myeloma, according to top-line results from part 2 of the phase IIb STORM trial reported by Karyopharm Therapeutics. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication